Members of the ESRC-funded REGenableMED project have published a number of Policy Briefings which explores a number of key factors that are likely to determine the progress of regenerative medicine therapies as they move towards the clinic. These briefings cover topics such as reimbursement and manufacturing, outline factors that are specific to the UK as well as more widely, and conclude with a series of priorities that policy needs to address. The Briefings are timely inasmuch as a new inquiry by the UK House of Commons Science and Technology Select Committee into regenerative medicine was announced in April 2016.